Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 35.86 as of 2026-10-06T14:41:51.633Z.
Consensus retrieved: 2026-10-06T11:28:09.273Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:41:51.633Z.
Quote observation: 2026-10-06T14:39:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b9a2d2db2be945c16edee98cba01b126f96cbf91f2738ca0190340e0e6f1b0bf
Forward PE Ratio (35.86) = Dated Quote Price ($10.16) / Consensus Forward EPS ($0.28)
FORWARD PE RATIO
35.86
SECTOR MEDIAN · HEALTHCARE
19.33
median of 154 covered companies
CURRENT VS SECTOR MEDIAN
+85.56%
vs the sector median at left
Fennec Pharmaceuticals Inc.
Market Cap
$352.93M
Forward PE Ratio
35.86
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | $352.93M | 35.86 |
| Embecta Corp. (EMBC)vs › | $352.99M | 3.38 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $359.28M | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $349.81M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $349.01M | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.25M | N/A |
| Canopy Growth Corporation (CGC)vs › | $370.48M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.23M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $333.18M | N/A |
| Agenus Inc. (AGEN)vs › | $333.14M | 29.91 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
35.9
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.16, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.28 | $0.20 – $0.37 | 4 | 35.9x |
| 2027-12-31 | $0.94 | $0.69 – $1.16 | 4 | 10.8x |
| 2028-12-31 | $1.64 | $0.94 – $2.00 | 3 | 6.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
